Immucothel (Immunocyanine, Standardised)

Immunocyanine is thought to interact with surface receptors on lymphocytes, modifying signaling pathways that regulate cytokine release and cellular activation. By influencing these immune pathways, the compound may alter the balance between immune stimulation and tolerance, which is the basis for its investigation as an immunomodulatory agent.

The dosing regimen for Immucothel is determined by the prescribing clinician based on the specific study protocol or therapeutic context. No standard dose is publicly established, and healthcare professionals tailor the amount, concentration, and frequency to the individual patient’s needs and the objectives of the clinical investigation.

Safety data for Immunocyanine during pregnancy or lactation are limited. The product should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians are advised to discuss the uncertainties with patients and consider alternative options when possible.

To request Immucothel, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the enquiry, the sales team will verify trade or institutional credentials and respond with pricing, availability, shipping details (including cold‑chain handling if required) and any necessary import documentation.

Immucothel belongs to a class of investigational immune‑modulating agents, whereas established alternatives such as monoclonal antibodies or cytokine inhibitors have well‑characterised efficacy and safety profiles. Compared with those agents, Immunocyanine’s data are still emerging, and its pharmacodynamic properties, dosing flexibility, and adverse‑event spectrum may differ, requiring careful evaluation in clinical trials.

Immucothel must be stored refrigerated at 2‑8 °C. The vials should be kept in their original packaging, protected from light, and should never be frozen or shaken. If a temporary temperature excursion occurs, the product should be inspected for visual changes before use, and any doubt about stability warrants discarding the material.

Immucothel is supplied as a sterile injectable solution for intradermal or subcutaneous injection. Administration must be performed by a qualified healthcare professional using aseptic technique. The injection site is typically selected on the upper arm, thigh, or abdomen, and the volume administered is dictated by the prescribing protocol.

The most serious adverse risks reported for Immucothel include anaphylactic reactions, severe hypersensitivity responses, and potential exacerbation of underlying autoimmune diseases. Patients should be monitored closely after administration for signs of respiratory distress, widespread rash, or sudden worsening of autoimmune symptoms, and emergency medical care should be available.

Immucothel should be avoided in individuals with a known hypersensitivity to Immunocyanine or any excipients in the formulation. Patients with severe immunodeficiency, uncontrolled autoimmune disorders, or those receiving live vaccines should not receive the product unless a specialist determines that the benefits outweigh the risks.